298 patents
Utility
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
4 Jan 24
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
Filed: 31 May 23
Utility
Topical Ruxolitinib for Treating Lichen Planus
28 Dec 23
The present disclosure relates to topical treatment of lichen planus (LP) using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Aaron R. MANGOLD, Ahmad B. NAIM
Filed: 1 Oct 21
Utility
Combination Therapy of ANTI-PD-1 Active Agent, ANTI-TIM-3 Active Agent, and ANTI-LAG-3 Active Agent for Treating Cancer
28 Dec 23
The present disclosure provides a combination therapy which comprises: (i) an active agent that binds PD-1 (e.g., an anti-PD-1 antibody), (ii) an active agent that binds TIM-3 (e.g., an anti-TIM-3 antibody), and/or (iii) an active agent that binds LAG-3 (e.g., an anti-LAG-3 antibody).
Paul E. Hoyle, Zhiwan Dong, Thomas Condamine, Nithya Srinivasan, John E. Janik, Kevin N. Heller
Filed: 6 Jun 23
Utility
Process of Preparing a PD-1/PD-L1 Inhibitor
21 Dec 23
The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
Filed: 31 Aug 23
Utility
Tricyclic Triazolo Compounds As DGK Inhibitors
14 Dec 23
The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Ding-Quan Qian, Xiaozhao Wang, Bo Wei, Meizhong Xu
Filed: 7 Jun 23
Utility
PD-L1/STING Conjugates and Methods of Use
14 Dec 23
The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
Liangxing Wu, Zhenwu Li, Wenqing Yao
Filed: 3 Jan 23
Utility
Solid Forms of Jak Inhibitor and Process of Preparing the Same
14 Dec 23
The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.
Zhongjiang Jia, Weiguo Liu, Pingli Liu, David Meloni, Yongchun Pan, Jiacheng Zhou, Travis Houston
Filed: 14 Jun 23
Utility
Topical Treatment of Vitiligo
16 Nov 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 16 Sep 21
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
9 Nov 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 8 Dec 22
Utility
Imidazopyrimidines and Triazolopyrimidines As A2A / A2B Inhibitors
9 Nov 23
Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
Filed: 13 Apr 23
Utility
ALK2 Inhibitors for the Treatment of Anemia
26 Oct 23
Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.
Francis Séguy, Ekaterine Asatiani, Yaoyu Chen
Filed: 28 Jun 23
Utility
Bicyclic Heterocycles As FGFR Inhibitors
26 Oct 23
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
Filed: 26 Jan 23
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
21 Sep 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof based on results from long term clinical studies.
Kathleen BUTLER, Jim Lee, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 28 Feb 23
Utility
Ruxolitinib Formulation for Reduction of Itch In Atopic Dermatitis
21 Sep 23
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 28 Oct 22
Utility
Tricyclic Urea Compounds As JAK2 V617F Inhibitors
21 Sep 23
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Zhitong Zheng, Eddy W. Yue
Filed: 16 Mar 23
Utility
Topical Formulation for a Jak Inhibitor
7 Sep 23
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 28 Dec 22
Utility
Solid Forms, Salts, and Processes of Preparation of a CDK2 Inhibitor
7 Sep 23
Joseph A. Sclafani, Daniel Carper, Zhongjiang Jia, Eric Shi, Aibin Zhang, Huaping Zhang, Wenxing Guo
Filed: 7 Mar 23
Utility
Anti-mutant Calreticulin (Calr) Antibodies and Uses Thereof
31 Aug 23
Anti-mutant calreticulin (mutCALR) antibodies are disclosed.
Patrick Mayes, Horacio G. Nastri, Rebecca A. Buonpane, Edimara S. Reis, Shaun M. Stewart, Jing Zhou, Marc C. Deller, Hsiang-Ting Lei, Leslie Brooke Epling McQuirter, Yonghong Zhao, Hamza Celik, Brittney Melissa Wass
Filed: 7 Dec 22
Utility
Combination Therapy Comprising an FGFR Inhibitor and a Kras Inhibitor
20 Jul 23
The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
Filed: 21 Nov 22
Utility
Heterocyclic Compounds As Immunomodulators
20 Jul 23
Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
Filed: 26 Sep 22